Search

everythinglearnresearchcommunity

for

Search:↓

The mRNA-1273 COVID-19 vaccine may worsen symptoms in people with systemic lupus erythematosus.

COVID-19 and vaccines cause various skin reactions and highlight the need for dermatologists in managing these issues and addressing vaccine distribution disparities.

The study concludes that long COVID recovery involves time, various treatments, and a strong patient-provider relationship.

New vaccine technologies are improving global health by making vaccines more effective and long-lasting.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

Nanoparticles can deliver vaccines through hair follicles, triggering immune responses and providing protection.

COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.

COVID-19 vaccines may cause hair loss in people who are genetically prone to it.

A patient experienced severe hair loss after getting an mRNA COVID-19 vaccine.

Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.

COVID-19 can cause long-term skin problems and has changed how skin doctors work.

COVID-19 infection and vaccination may trigger hair loss and rapid hair whitening.

COVID-19 can worsen autoimmune skin diseases and increase their occurrence.

COVID-19 mRNA vaccines may increase the risk of flare-ups in certain inflammatory diseases.

Most skin reactions to COVID-19 vaccines in India were mild and not a reason to avoid vaccination.

Vaccination is crucial for psoriasis patients on immunosuppressive therapy to manage COVID-19 risks.

Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.

The Pfizer COVID-19 vaccine may rarely trigger nail psoriasis.

A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.

Dissolving microneedles offer efficient, minimally invasive drug delivery through the skin.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

People in high-income countries are more likely to accept COVID-19 booster doses than those in middle or low-income countries.

BCG site reactions after COVID-19 mRNA vaccination are mild, temporary, and likely under-reported.

COVID-19 vaccination may slightly increase the risk of hair loss, but benefits outweigh this risk.

The study aims to create a model to predict health attributes using diverse health data from Japanese adults.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

Gene therapy shows promise for treating skin disorders and cancer, but faces technical challenges.

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

Self-amplifying RNA could be a better option for protein replacement therapy with lower doses and lasting effects, but delivering it into cells is still challenging.

Females generally have stronger immune responses than males due to the X chromosome.